The FDA has expanded the approval of Dextenza (dexamethasone ophthalmic insert) to include pediatric treatment.

The FDA has accepted for review a resubmission of the BLA for bevacizumab-vikg (ONS-5010) for the treatment of wet AMD.

Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative inflammatory reaction.